People In The News: CEO Post Changes Hands At Express Scripts, Xenoport, Promethera, Molecular Response, Protagonist
Executive Summary
NACDS and USP also bring on new execs; more personnel changes in this month's column.
You may also be interested in...
CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.